bullish•Yichang HEC Changjiang Pharma•27 Nov 2022 05:15
HEC Pharma (1558 HK): Core Product Saw Volume Recovery in 1H 2022; New Launches to Accelerate Growth
HEC Pharma’s revenue jumped ~6x in 1H22, driven by volume recovery of its core drug Kewei. Going ahead, new generic launches and insulin portfolio...
bullish•Guangzhou R&F Properties•17 Jul 2020 12:49
Full Circulation Of H-Shares - July Update
This update is the latest in a series dating back to Legend's Conversion of Domestic Shares in June 2018, with the most recent addition CPPCC And...
bullish•Thematic (Sector/Industry)•23 Dec 2022 14:05
2022 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe
From my coverage universe, two Taiwanese stocks generated 59% and 71% returns in nearly six months. New product launch and geography expansion are...
bearish•Quantitative Analysis•12 Dec 2022 08:15
Hong Kong Connect Flows (Dec 9th): HKEx, Ping An H&T, Tencent, Xiaomi, Li Ning, Meituan
We analyzed southbound Hong Kong connect flows in the past week and highlight flows for HKEx, Ping An H&T, Tencent, Xiaomi, Li Ning, Meituan,...
bullish•Yichang HEC Changjiang Pharma•24 Nov 2021 18:12